Vertex Triple-Data Combos Live Up To High Hopes In Early Studies

Phase I and II results for three of Vertex's four next-generation CFTR correctors showed positive effects on pulmonary function when added to two of the company's approved cystic fibrosis therapies. The drugs are moving rapidly forward so that one or two can move into pivotal trials in 2018.